U.S. health authorities are closely tracking the aftermath of a hantavirus outbreak aboard the luxury cruise ship MV Hondius, which has already claimed three lives and raised international health concerns. The Centers for Disease Control and Prevention (CDC) confirmed Wednesday that several American travelers who were on the expedition cruise are now being monitored across multiple U.S. states.
According to the World Health Organization (WHO), the outbreak resulted in the deaths of a Dutch couple and a German citizen. In addition, eight other passengers, including a Swiss national, are suspected of contracting the virus. Hantavirus is a rare but potentially deadly disease that is commonly spread through contact with infected rodents or their droppings. Human-to-human transmission remains extremely uncommon.
The CDC stated that the U.S. Department of State is leading a coordinated response involving direct communication with passengers, international health agencies, and domestic public health officials. Authorities emphasized that the current risk to the general American public remains very low.
Reports indicate that health officials in Georgia, Arizona, and California are monitoring passengers who recently returned from the cruise. The Georgia Department of Public Health confirmed that two residents are under observation after disembarking from the ship. Officials said both individuals are in good health, showing no symptoms, and are following CDC recommendations.
Meanwhile, Arizona health officials are also monitoring one resident who traveled aboard the MV Hondius. The passenger has not displayed any symptoms linked to hantavirus infection. California authorities have not yet released details regarding the number of residents being observed.
The outbreak aboard the MV Hondius has drawn global attention as health agencies continue efforts to contain the situation and prevent further infections in 2026.


US to Withdraw 5,000 Troops from Germany Amid Growing Rift with European Allies
Daiichi Sankyo Stock Drops After Earnings Delay and Oncology Review
Judge Rules Use of Military Lawyers in Civilian Prosecutions Is Lawful
Why the future of marijuana legalization remains hazy despite high public support
Innovent Biologics Shares Rally on New Eli Lilly Oncology and Immunology Deal
Medicare to Cover GLP-1 Weight-Loss and Diabetes Drugs Starting July 1
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes
FDA Warns Novo Nordisk Over Misleading Ozempic Ad Claims
The four types of dementia most people don’t know exist
Organon Stock Surges After Reports of $13 Billion Buyout Bid by Sun Pharma
U.S. Warns Allies Over Alleged Chinese AI IP Theft Linked to DeepSeek
Weight-Loss Drug Ads Take Over the Super Bowl as Pharma Embraces Direct-to-Consumer Marketing
Google Secures Pentagon AI Deal for Classified Projects
Trump Administration Dismisses Entire National Science Board, Raising Concerns Over Scientific Independence
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 



